Balyasny Asset Management
KPTI icon

Balyasny Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Balyasny Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-70,748
Closed -$394K – 3275
2026
Q1 		$394K Buy
+70,748
New +$539K ﹤0.01% 2459
2024
Q3 		– Sell
-1,504
Closed -$19.6K – 2958
2024
Q2 		$19.6K Buy
+1,504
New +$24.9K ﹤0.01% 2472
2023
Q1 		– Sell
-817
Closed -$41.6K – 2922
2022
Q4 		$41.6K Sell
817
-38,887
-98% -$2.7M ﹤0.01% 2370
2022
Q3 		$3.25M Buy
39,704
+33,967
+592% +$2.54M 0.01% 1234
2022
Q2 		$388K Sell
5,737
-17,095
-75% -$1.57M ﹤0.01% 2052
2022
Q1 		$2.52M Buy
+22,832
New +$2.85M 0.01% 1259
2021
Q4 		– Sell
-13,361
Closed -$1.17M – 2437
2021
Q3 		$1.17M Buy
13,361
+10,051
+304% +$1.04M ﹤0.01% 1293
2021
Q2 		$512K Sell
3,310
-16,102
-83% -$2.34M ﹤0.01% 1543
2021
Q1 		$3.06M Sell
19,412
-4,755
-20% -$1M 0.02% 875
2020
Q4 		$5.61M Buy
+24,167
New +$5.6M 0.03% 601
2020
Q3 		– Sell
-14,870
Closed -$4.22M – 1451
2020
Q2 		$4.22M Buy
+14,870
New +$4.4M 0.04% 559
2019
Q1 		– Sell
-2,764
Closed -$389K – 1515
2018
Q4 		$389K Buy
2,764
+253
+10% +$42.7K ﹤0.01% 1157
2018
Q3 		$641K Buy
+2,511
New +$694K ﹤0.01% 1310
2016
Q1 		– Sell
-960
Closed -$191K – 1405
2015
Q4 		$191K Sell
960
-180
-16% -$39K ﹤0.01% 1096
2015
Q3 		$180K Buy
+1,140
New +$305K ﹤0.01% 1017
2014
Q4 		– Sell
-6,642
Closed -$3.48M – 759
2014
Q3 		$3.48M Buy
+6,642
New +$3.75M 0.03% 529

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Balyasny Asset Management's KPTI Position: Q2 2026 in Review

Balyasny Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2026, closing a stake of 70,748 shares — an estimated $394K sold.

Balyasny Asset Management first reported a position in KPTI in Q3 2014 and held it in 16 quarters. The position peaked at $5.61M in Q4 2020. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Balyasny Asset Management reported no remaining Karyopharm Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 70,748 Karyopharm Therapeutics shares in Q2 2026, an estimated $394K.
  • Balyasny Asset Management first reported a position in Karyopharm Therapeutics in Q3 2014 and held it in 16 quarters.
  • Balyasny Asset Management's Karyopharm Therapeutics position peaked at $5.61M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.